Lymphoma & Plasma Cell Disorders
From the Journals
Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant
But only if caregivers are equipped for outpatient care.
Conference Coverage
On the horizon: Asciminib, a new drug for treating r/r CML
“Although we have many excellent therapies for CML, having a new medication that targets BCR-ABL in a novel way is still welcome to help us better...
Conference Coverage
Four-item prognostic index predicts survival in adult Burkitt lymphoma
Conference Coverage
Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma
Conference Coverage
Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL
Conference Coverage
Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies
Conference Coverage
ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma
Conference Coverage
Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL
Conference Coverage
Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL
From the Journals
Extended virus shedding after COVID-19 in some patients with cancer
Some patients, including stem cell transplant and CAR T recipients, may require extended periods of isolation.
Conference Coverage
Five-minute SC injection of daratumumab in RRMM
“The appeal of subcutaneous daratumumab is the 5 minutes it needs for administering, cutting down considerable on ‘chair/clinic’ time.”